Loading...

Purified anti-mouse IL-17A Antibody Purified anti-mouse IL-17A Antibody

Pricing & Availability
Clone
TC11-18H10.1 (See other available formats)
Regulatory Status
RUO
Other Names
Interleukin-17, Cytotoxic T lymphocyte-associated antigen 8 (CTLA-8)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
mIL-17A_040408
  • mIL-17A_040408
Compare all formats
Cat # Size Price Quantity Check Availability Save
506902 500 µg NOK2327
Check Availability


Need larger quantities of this item?
Request Bulk Quote
506901 50 µg NOK875
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IL-17, also known as CTLA-8, is a T cell-expressed pleiotropic cytokine that exhibits a high degree of homology to a protein encoded by the ORF13 gene of herpes virus Saimiri. IL-17 is produced by Th cells (Th17) that are distinct from the traditional Th1- and Th2-cell subsets. IL-23 plays an important role in triggering IL-17 production. Both recombinant and natural IL-17 have been shown to exist as disulfide linked homodimers. IL-17 exhibits multiple biological activities on a variety of cells including: the induction of IL-6 and IL-8 production in fibroblasts, activation of NF-κB, and costimulation of T cell proliferation. IL-17 is an essential inflammatory mediator in the development of autoimmune diseases. Neutralization of IL-17 with monoclonal antibody is able to ameliorate the disease course.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli expressed, recombinant mouse IL-17A
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

ELISA Capture - Quality tested
CyTOF® - Verified
ELISPOT Capture, ICFC - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by ELISA assay. For ELISA capture, a concentration range of 1-4 µg/ml is recommended. To obtain a linear standard curve, serial dilutions of IL-17 recombinant protein ranging from 1000 to 15.63 pg/mL are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

ELISA Capture3,4 and ELISPOT Capture5: The purified TC11-18H10.1 antibody is useful as the capture antibody in a sandwich ELISA, when used in conjunction with the biotinylated TC11-8H4 antibody (Cat. No. 507002) as the detecting antibody and recombinant mouse IL-17 (Cat. No. 576009) as the standard.
Flow Cytometry2-4,7,8,11,12: The TC11-18H10.1 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IL-17-producing cells within mixed cell populations.
Neutralization6,9: The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IL-17 bioactivity in vivo and in vitro (Cat. No. 506906).

Application References
  1. Kennedy J, et al. 1996. J. Interferon Cytokine Res. 16:611.
  2. Schubert D, et al. 2004. J. Immunol. 172:4503. (ICFC)
  3. Infante-Duarte C, et al. 2000. J. Immunol. 165:6107. (ICFC, ELISA Capture)
  4. Harrington LE, et al. 2005. Nature Immunol. doi:10.1038/ni1254. (ICFC, ELISA Capture)
  5. Nekrasova T, et al. 2005. J. Immunol. 175:2734. (ELISPOT Capture)
  6. Yen D, et al. 2006. J. Clin. Invest. 116:1310. (Neut)
  7. Ehirchiou D, et al. 2007. J. Exp. Med. 204:1519. (ICFC)
  8. Kang SG, et al. 2007. J. Immunol. 179:3724. (ICFC)
  9. Smith E, et al. 2008. J. Immunol. 181:1357. (Neut) PubMed
  10. Neufert C, et al. 2007. Eur. J. Immunol. 37:1809. PubMed
  11. Wang C, et al. 2009. Mucosal Immunol 2:173. (ICFC) PubMed
  12. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (ICFC) PubMed
  13. Kivisäkk P, et al. 2009. Ann. Neurol. 65:457. PubMed
  14. Cooney LA, et al. 2011. J. Immunol. 187:4440. PubMed
  15. Ma Y, et al. 2012. PLoS One. 7:e40763. PubMed
  16. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
Product Citations
  1. Zhang S, et al. 2017. Nature.. 10.1038/nature24283. PubMed
  2. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  3. Wolf Y, et al. 2017. J Exp Med. 214:905. PubMed
  4. Yeola AP, et al. 2020. Front Immunol. 10:3115. PubMed
  5. Paterson MJ, et al. 2020. PLoS Pathog. 16:e1008733. PubMed
  6. Yan J, et al. 2020. Cancer Discov. 10:124. PubMed
  7. Yu H, et al. 2020. Front Immunol. 11:1773. PubMed
  8. Altemus J, et al. 2022. J Cell Physiol. 237:3001. PubMed
  9. Sato A, et al. 2022. Biol Pharm Bull. 45:1798. PubMed
  10. Burrello C, et al. 2018. Front Med (Lausanne). 5:21. PubMed
  11. Landuyt AE, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  12. Guo R, et al. 2020. Cell Res. 30:21. PubMed
  13. Wang W, et al. 2018. Cancer Cell. 34:757. PubMed
  14. Arnold IC, et al. 2018. J Exp Med. 215:2055. PubMed
  15. Yang J, et al. 2020. Front Immunol. 10:3048. PubMed
  16. He Z, et al. 2017. J Immunol. 199:955. PubMed
  17. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  18. Dienz O, et al. 2020. J Immunol. 204:1521. PubMed
  19. Draganov D, et al. 2021. NPJ Breast Cancer. 7:22. PubMed
  20. Volchenkov R, et al. 2017. Front Immunol. 0.818055556. PubMed
  21. Cooney L, et al. 2011. J Immunol. 187:4440. PubMed
  22. Mencarelli A, et al. 2018. Front Immunol. 9:261. PubMed
  23. Kaisar MMM, et al. 2018. PLoS Biol. 16:e2005504. PubMed
  24. Mayer KA, et al. 2021. FASEB J. 35:e21217. PubMed
  25. Hua J, et al. 2018. Sci Rep. 5.235416667. PubMed
  26. Ma Y, et al. 2012. PLoS One. 7:e40763. PubMed
  27. Gartlan KH, et al. 2019. Blood Adv. 2.110416667. PubMed
  28. Abboud G, et al. 2018. Front Immunol. 9:1973. PubMed
  29. Chen Y, et al. 2017. J Autoimmun. 77:96. PubMed
  30. Cardoso F, et al. 2021. Nature. 597:410. PubMed
  31. Yoon S, et al. 2020. Antioxidants (Basel). 10:. PubMed
  32. Matsuo K, et al. 2018. J Invest Dermatol. 138:1764. PubMed
  33. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  34. Oyler‐Yaniv J et al. 2017. Molecular cell. 66(5):635-647 . PubMed
  35. Karmaus PWF, et al. 2019. Nature. 565:101. PubMed
  36. Muhammad F, et al. 2020. J Autoimmun. 111:102441. PubMed
  37. Takeuchi Y, et al. 2021. Sci Rep. 11:18679. PubMed
  38. Wang Y, et al. 2021. Front Immunol. 11:601601. PubMed
  39. Jain A, et al. 2020. Nat Immunol. 0.920138889. PubMed
  40. Nguyen H, et al. 2020. Clin Cancer Res. 26:3481. PubMed
  41. Smith E, et al. 2008. J Immunol. 181:1357. PubMed
  42. Jordan J, et al. 2008. Infect Immun. 76:3717. PubMed
  43. Kästele V, et al. 2021. Mucosal Immunol. 14:717. PubMed
  44. Zhang S, et al. 2017. Nature.. 10.1038/nature24283. PubMed
  45. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  46. Wolf Y, et al. 2017. J Exp Med. 214:905. PubMed
  47. Yeola AP, et al. 2020. Front Immunol. 10:3115. PubMed
  48. Paterson MJ, et al. 2020. PLoS Pathog. 16:e1008733. PubMed
  49. Yan J, et al. 2020. Cancer Discov. 10:124. PubMed
  50. Yu H, et al. 2020. Front Immunol. 11:1773. PubMed
  51. Altemus J, et al. 2022. J Cell Physiol. 237:3001. PubMed
  52. Sato A, et al. 2022. Biol Pharm Bull. 45:1798. PubMed
  53. Burrello C, et al. 2018. Front Med (Lausanne). 5:21. PubMed
  54. Landuyt AE, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  55. Guo R, et al. 2020. Cell Res. 30:21. PubMed
  56. Wang W, et al. 2018. Cancer Cell. 34:757. PubMed
  57. Arnold IC, et al. 2018. J Exp Med. 215:2055. PubMed
  58. Yang J, et al. 2020. Front Immunol. 10:3048. PubMed
  59. He Z, et al. 2017. J Immunol. 199:955. PubMed
  60. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  61. Dienz O, et al. 2020. J Immunol. 204:1521. PubMed
  62. Draganov D, et al. 2021. NPJ Breast Cancer. 7:22. PubMed
  63. Volchenkov R, et al. 2017. Front Immunol. 0.818055556. PubMed
  64. Cooney L, et al. 2011. J Immunol. 187:4440. PubMed
  65. Mencarelli A, et al. 2018. Front Immunol. 9:261. PubMed
  66. Kaisar MMM, et al. 2018. PLoS Biol. 16:e2005504. PubMed
  67. Mayer KA, et al. 2021. FASEB J. 35:e21217. PubMed
  68. Hua J, et al. 2018. Sci Rep. 5.235416667. PubMed
  69. Ma Y, et al. 2012. PLoS One. 7:e40763. PubMed
  70. Gartlan KH, et al. 2019. Blood Adv. 2.110416667. PubMed
  71. Abboud G, et al. 2018. Front Immunol. 9:1973. PubMed
  72. Chen Y, et al. 2017. J Autoimmun. 77:96. PubMed
  73. Cardoso F, et al. 2021. Nature. 597:410. PubMed
  74. Yoon S, et al. 2020. Antioxidants (Basel). 10:. PubMed
  75. Matsuo K, et al. 2018. J Invest Dermatol. 138:1764. PubMed
  76. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  77. Oyler‐Yaniv J et al. 2017. Molecular cell. 66(5):635-647 . PubMed
  78. Karmaus PWF, et al. 2019. Nature. 565:101. PubMed
  79. Muhammad F, et al. 2020. J Autoimmun. 111:102441. PubMed
  80. Takeuchi Y, et al. 2021. Sci Rep. 11:18679. PubMed
  81. Wang Y, et al. 2021. Front Immunol. 11:601601. PubMed
  82. Jain A, et al. 2020. Nat Immunol. 0.920138889. PubMed
  83. Nguyen H, et al. 2020. Clin Cancer Res. 26:3481. PubMed
  84. Smith E, et al. 2008. J Immunol. 181:1357. PubMed
  85. Jordan J, et al. 2008. Infect Immun. 76:3717. PubMed
  86. Kästele V, et al. 2021. Mucosal Immunol. 14:717. PubMed
RRID
AB_315462 (BioLegend Cat. No. 506902)
AB_315461 (BioLegend Cat. No. 506901)

Antigen Details

Structure
Cytokine; dimer; 15 kD (Mammalian).
Bioactivity
Secretion of IL-6, IL-8, G-CSF, prostaglandin E2 by epithelial, endothelial or fibroblastic cells; stimulates cell migration, cord formation, and IL-6 secretion by stromal cells
Cell Sources
CD4+ memory T cells
Cell Targets
Fibroblasts, epithelial and endothelial cells, stromal cells
Receptors
IL-17R (CD217)
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. Numasaki M, et al. 2002. Blood 101:2620.
3. Fossiez F, et al. 1996. J. Exp. Med. 183:2593.
4. Yao Z, et al. 1997. Cytokine 9:794.
5. Dong C. 2006. Nat. Rev. Immunol. 6:329.
6. Hofstetter HH, et al. 2005 Cell. Immunol. 237:123.

Gene ID
16171 View all products for this Gene ID
UniProt
View information about IL-17A on UniProt.org

Related FAQs

Does the anti-mouse IL-17 antibody (clone TC11-18H10.1) recognize the A or F isoform?
Clone TC11-18H10.1 recognizes IL-17A isoform, but it also recognizes the IL-17A/F heterodimer via IL-17A binding.
Go To Top Version: 4    Revision Date: 06.14.2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
TC11-18H10.1 (See other available formats)
Regulatory Status
RUO
Other Names
Interleukin-17, Cytotoxic T lymphocyte-associated antigen 8 (CTLA-8)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
mIL-17A_040408
  • mIL-17A_040408
Compare all formats
Cat # Size Price Quantity Check Availability Save
506902 500 µg NOK2327
Check Availability


Need larger quantities of this item?
Request Bulk Quote
506901 50 µg NOK875
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IL-17, also known as CTLA-8, is a T cell-expressed pleiotropic cytokine that exhibits a high degree of homology to a protein encoded by the ORF13 gene of herpes virus Saimiri. IL-17 is produced by Th cells (Th17) that are distinct from the traditional Th1- and Th2-cell subsets. IL-23 plays an important role in triggering IL-17 production. Both recombinant and natural IL-17 have been shown to exist as disulfide linked homodimers. IL-17 exhibits multiple biological activities on a variety of cells including: the induction of IL-6 and IL-8 production in fibroblasts, activation of NF-κB, and costimulation of T cell proliferation. IL-17 is an essential inflammatory mediator in the development of autoimmune diseases. Neutralization of IL-17 with monoclonal antibody is able to ameliorate the disease course.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli expressed, recombinant mouse IL-17A
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

ELISA Capture - Quality tested
CyTOF® - Verified
ELISPOT Capture, ICFC - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by ELISA assay. For ELISA capture, a concentration range of 1-4 µg/ml is recommended. To obtain a linear standard curve, serial dilutions of IL-17 recombinant protein ranging from 1000 to 15.63 pg/mL are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

ELISA Capture3,4 and ELISPOT Capture5: The purified TC11-18H10.1 antibody is useful as the capture antibody in a sandwich ELISA, when used in conjunction with the biotinylated TC11-8H4 antibody (Cat. No. 507002) as the detecting antibody and recombinant mouse IL-17 (Cat. No. 576009) as the standard.
Flow Cytometry2-4,7,8,11,12: The TC11-18H10.1 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IL-17-producing cells within mixed cell populations.
Neutralization6,9: The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IL-17 bioactivity in vivo and in vitro (Cat. No. 506906).

Application References
  1. Kennedy J, et al. 1996. J. Interferon Cytokine Res. 16:611.
  2. Schubert D, et al. 2004. J. Immunol. 172:4503. (ICFC)
  3. Infante-Duarte C, et al. 2000. J. Immunol. 165:6107. (ICFC, ELISA Capture)
  4. Harrington LE, et al. 2005. Nature Immunol. doi:10.1038/ni1254. (ICFC, ELISA Capture)
  5. Nekrasova T, et al. 2005. J. Immunol. 175:2734. (ELISPOT Capture)
  6. Yen D, et al. 2006. J. Clin. Invest. 116:1310. (Neut)
  7. Ehirchiou D, et al. 2007. J. Exp. Med. 204:1519. (ICFC)
  8. Kang SG, et al. 2007. J. Immunol. 179:3724. (ICFC)
  9. Smith E, et al. 2008. J. Immunol. 181:1357. (Neut) PubMed
  10. Neufert C, et al. 2007. Eur. J. Immunol. 37:1809. PubMed
  11. Wang C, et al. 2009. Mucosal Immunol 2:173. (ICFC) PubMed
  12. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (ICFC) PubMed
  13. Kivisäkk P, et al. 2009. Ann. Neurol. 65:457. PubMed
  14. Cooney LA, et al. 2011. J. Immunol. 187:4440. PubMed
  15. Ma Y, et al. 2012. PLoS One. 7:e40763. PubMed
  16. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
Product Citations
  1. Zhang S, et al. 2017. Nature.. 10.1038/nature24283. PubMed
  2. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  3. Wolf Y, et al. 2017. J Exp Med. 214:905. PubMed
  4. Yeola AP, et al. 2020. Front Immunol. 10:3115. PubMed
  5. Paterson MJ, et al. 2020. PLoS Pathog. 16:e1008733. PubMed
  6. Yan J, et al. 2020. Cancer Discov. 10:124. PubMed
  7. Yu H, et al. 2020. Front Immunol. 11:1773. PubMed
  8. Altemus J, et al. 2022. J Cell Physiol. 237:3001. PubMed
  9. Sato A, et al. 2022. Biol Pharm Bull. 45:1798. PubMed
  10. Burrello C, et al. 2018. Front Med (Lausanne). 5:21. PubMed
  11. Landuyt AE, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  12. Guo R, et al. 2020. Cell Res. 30:21. PubMed
  13. Wang W, et al. 2018. Cancer Cell. 34:757. PubMed
  14. Arnold IC, et al. 2018. J Exp Med. 215:2055. PubMed
  15. Yang J, et al. 2020. Front Immunol. 10:3048. PubMed
  16. He Z, et al. 2017. J Immunol. 199:955. PubMed
  17. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  18. Dienz O, et al. 2020. J Immunol. 204:1521. PubMed
  19. Draganov D, et al. 2021. NPJ Breast Cancer. 7:22. PubMed
  20. Volchenkov R, et al. 2017. Front Immunol. 0.818055556. PubMed
  21. Cooney L, et al. 2011. J Immunol. 187:4440. PubMed
  22. Mencarelli A, et al. 2018. Front Immunol. 9:261. PubMed
  23. Kaisar MMM, et al. 2018. PLoS Biol. 16:e2005504. PubMed
  24. Mayer KA, et al. 2021. FASEB J. 35:e21217. PubMed
  25. Hua J, et al. 2018. Sci Rep. 5.235416667. PubMed
  26. Ma Y, et al. 2012. PLoS One. 7:e40763. PubMed
  27. Gartlan KH, et al. 2019. Blood Adv. 2.110416667. PubMed
  28. Abboud G, et al. 2018. Front Immunol. 9:1973. PubMed
  29. Chen Y, et al. 2017. J Autoimmun. 77:96. PubMed
  30. Cardoso F, et al. 2021. Nature. 597:410. PubMed
  31. Yoon S, et al. 2020. Antioxidants (Basel). 10:. PubMed
  32. Matsuo K, et al. 2018. J Invest Dermatol. 138:1764. PubMed
  33. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  34. Oyler‐Yaniv J et al. 2017. Molecular cell. 66(5):635-647 . PubMed
  35. Karmaus PWF, et al. 2019. Nature. 565:101. PubMed
  36. Muhammad F, et al. 2020. J Autoimmun. 111:102441. PubMed
  37. Takeuchi Y, et al. 2021. Sci Rep. 11:18679. PubMed
  38. Wang Y, et al. 2021. Front Immunol. 11:601601. PubMed
  39. Jain A, et al. 2020. Nat Immunol. 0.920138889. PubMed
  40. Nguyen H, et al. 2020. Clin Cancer Res. 26:3481. PubMed
  41. Smith E, et al. 2008. J Immunol. 181:1357. PubMed
  42. Jordan J, et al. 2008. Infect Immun. 76:3717. PubMed
  43. Kästele V, et al. 2021. Mucosal Immunol. 14:717. PubMed
  44. Zhang S, et al. 2017. Nature.. 10.1038/nature24283. PubMed
  45. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  46. Wolf Y, et al. 2017. J Exp Med. 214:905. PubMed
  47. Yeola AP, et al. 2020. Front Immunol. 10:3115. PubMed
  48. Paterson MJ, et al. 2020. PLoS Pathog. 16:e1008733. PubMed
  49. Yan J, et al. 2020. Cancer Discov. 10:124. PubMed
  50. Yu H, et al. 2020. Front Immunol. 11:1773. PubMed
  51. Altemus J, et al. 2022. J Cell Physiol. 237:3001. PubMed
  52. Sato A, et al. 2022. Biol Pharm Bull. 45:1798. PubMed
  53. Burrello C, et al. 2018. Front Med (Lausanne). 5:21. PubMed
  54. Landuyt AE, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  55. Guo R, et al. 2020. Cell Res. 30:21. PubMed
  56. Wang W, et al. 2018. Cancer Cell. 34:757. PubMed
  57. Arnold IC, et al. 2018. J Exp Med. 215:2055. PubMed
  58. Yang J, et al. 2020. Front Immunol. 10:3048. PubMed
  59. He Z, et al. 2017. J Immunol. 199:955. PubMed
  60. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  61. Dienz O, et al. 2020. J Immunol. 204:1521. PubMed
  62. Draganov D, et al. 2021. NPJ Breast Cancer. 7:22. PubMed
  63. Volchenkov R, et al. 2017. Front Immunol. 0.818055556. PubMed
  64. Cooney L, et al. 2011. J Immunol. 187:4440. PubMed
  65. Mencarelli A, et al. 2018. Front Immunol. 9:261. PubMed
  66. Kaisar MMM, et al. 2018. PLoS Biol. 16:e2005504. PubMed
  67. Mayer KA, et al. 2021. FASEB J. 35:e21217. PubMed
  68. Hua J, et al. 2018. Sci Rep. 5.235416667. PubMed
  69. Ma Y, et al. 2012. PLoS One. 7:e40763. PubMed
  70. Gartlan KH, et al. 2019. Blood Adv. 2.110416667. PubMed
  71. Abboud G, et al. 2018. Front Immunol. 9:1973. PubMed
  72. Chen Y, et al. 2017. J Autoimmun. 77:96. PubMed
  73. Cardoso F, et al. 2021. Nature. 597:410. PubMed
  74. Yoon S, et al. 2020. Antioxidants (Basel). 10:. PubMed
  75. Matsuo K, et al. 2018. J Invest Dermatol. 138:1764. PubMed
  76. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  77. Oyler‐Yaniv J et al. 2017. Molecular cell. 66(5):635-647 . PubMed
  78. Karmaus PWF, et al. 2019. Nature. 565:101. PubMed
  79. Muhammad F, et al. 2020. J Autoimmun. 111:102441. PubMed
  80. Takeuchi Y, et al. 2021. Sci Rep. 11:18679. PubMed
  81. Wang Y, et al. 2021. Front Immunol. 11:601601. PubMed
  82. Jain A, et al. 2020. Nat Immunol. 0.920138889. PubMed
  83. Nguyen H, et al. 2020. Clin Cancer Res. 26:3481. PubMed
  84. Smith E, et al. 2008. J Immunol. 181:1357. PubMed
  85. Jordan J, et al. 2008. Infect Immun. 76:3717. PubMed
  86. Kästele V, et al. 2021. Mucosal Immunol. 14:717. PubMed
RRID
AB_315462 (BioLegend Cat. No. 506902)
AB_315461 (BioLegend Cat. No. 506901)

Antigen Details

Structure
Cytokine; dimer; 15 kD (Mammalian).
Bioactivity
Secretion of IL-6, IL-8, G-CSF, prostaglandin E2 by epithelial, endothelial or fibroblastic cells; stimulates cell migration, cord formation, and IL-6 secretion by stromal cells
Cell Sources
CD4+ memory T cells
Cell Targets
Fibroblasts, epithelial and endothelial cells, stromal cells
Receptors
IL-17R (CD217)
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. Numasaki M, et al. 2002. Blood 101:2620.
3. Fossiez F, et al. 1996. J. Exp. Med. 183:2593.
4. Yao Z, et al. 1997. Cytokine 9:794.
5. Dong C. 2006. Nat. Rev. Immunol. 6:329.
6. Hofstetter HH, et al. 2005 Cell. Immunol. 237:123.

Gene ID
16171 View all products for this Gene ID
UniProt
View information about IL-17A on UniProt.org

Related FAQs

Does the anti-mouse IL-17 antibody (clone TC11-18H10.1) recognize the A or F isoform?
Clone TC11-18H10.1 recognizes IL-17A isoform, but it also recognizes the IL-17A/F heterodimer via IL-17A binding.
Go To Top Version: 4    Revision Date: 06.14.2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account